Synthetic Genomics Market

Global Synthetic Genomics Market: Global Size, Trends, Competitive, and Historical & Forecast Analysis, 2024-2030: The market is anticipated to rise due to improvements in genetic engineering and biotechnology, intensifying demand for personalized medicine, and progress in DNA synthesis and sequencing technologies.

Global Synthetic Genomics Market is valued at US$ 3.5 Billion in 2024, and it is expected to reach US$ 18.5 Million by 2030 with a CAGR of 27.3 % over the forecast period.

Scope of Global Synthetic Genomics Market Report:

Synthetic genomics is a cutting-edge pitch of biotechnology intensive on designing and creating wholly new genomes or modifying existing ones using synthetic biology techniques. By constructing long aspects of DNA from chemical building blocks and assembling them into functional genes or whole genomes, scientists can plot organisms with tailored genetic traits for specific purposes. The aims of synthetic genomics often to design entirely new life or optimize the biological functions from the ground up. Moreover, in the early 1970s, Har Gobind Khorana, a molecular biologist, developed the first artificial gene. His work proved that it was possible to create functional DNA sequences chemically. Also, the field gained historical significance in 2010 when scientists at JCVI constructed the first cell with a synthetic genome.

Applications of synthetic genomics extend to various industries. In biotechnology, plotted microorganisms are developed to produce biofuels, presenting a sustainable alternative to fossil fuels by converting biomass into renewable energy bases. On the other hand, in agriculture, synthetic genomics improves the resistant capacity of crops to diseases, pests as well as environmental stressors and majorly helps to increase the crop yield and sustainability. However, in medicine, it helps to create the gene therapies and customized vaccines to increase the personalized genetic makeup and medicine. Additionally, synthetic genomics is the origin of life and capable of creating artificial life which helps to cover the future biotechnological innovations across the medical sectors.

Key Players of Global Synthetic Genomics Market Report:

Some of the prominent players in the global Synthetic Genomics market includes Agilent Technologies, Aldevron, Amyris, Inc., ATUM, Beijing Genomics Institute (BGI), Blue Heron Biotech, Cellectis, Codexis, Inc., CRISPR Therapeutics, DNA Script, eGenesis Eurofins Genomics, Genomatica, Genscript Biotech Corporation, Ginkgo Bioworks, Illumina, Inc., Inscripta, Integrated DNA Technologies (IDT), Novozymes, OriGene Technologies, Inc., Precigen, Sangamo Therapeutics, Synthego, Telesis Bio, Thermo Fisher Scientific, Twist Bioscience and Others.

Market Drivers:

Technological advancement boosts the global synthetic genomics market growth in the forecast period.

Gene editing technologies drive the market growth due to increasing the use of various tools such as CRISPR-Cas9, TALENs (Transcription Activator-Like Effector Nucleases), and Zinc Finger Nucleases (ZFNs) has changed the situation of synthetic genomics. Now, this technology helps scientists to modify DNA with incredible precision, allowing specific changes to genetic material. Moreover, CRISPER-Cas9 technology has become widely used due to providing more accurate data rather than older methods. For instance, STEMCELL technologies published data that showed 59% of researchers have used CRISPR-Cas9 in the past five years, and 17% plan to use it soon.

However, these tools assist scientists to competently edit, insert, or remove specific genes, and help to innovations in various industries like healthcare, agriculture, and industrial biotechnology. The capability of providing accurately alter genes has speed up the development of synthetic biology innovations such as gene therapies, GMOs and bioengineering organisms for industrial applications. Overall, all these technologies available at a lower cost, help to increase efficiencies of gene editing technologies and shaping the future of biotechnology and life sciences.

Government and private investments are catalyzing the growth of synthetic genomics in various industries.

Government and private investments have significantly contributed to the growth of the synthetic genomics market. In the last some years, various governments in globe have renowned the potential of synthetic biology and genomics to advance fields such as medicine, agriculture, and industrial biotechnology & as a result these government have increased funding for genomic research & development through various resources including grants, subsidies and public private partnerships.

Simultaneously, private institutions and venture capitalists are actively investing in synthetic genomics organizations, driving commercialization efforts. Moreover, startups and established players are benefiting from these financial inflows, enabling them to expand research, scale operations, and accelerate the market introduction of cutting-edge genomic solutions. For example, in 2024, Constructive Bio, a synthetic genomics startup, secured US$ 58 million in Series A funding. Similarly, the Carl Zeiss Foundation committed US$ 12.9 million to establish a new Synthetic Genomics Research Institute in the same year.

Additionally, for speeding up research and innovation, the National Institutes of Health (NIH) in the U.S. and Horizon Europe in the European Union have also allocated significant resources toward synthetic biology initiatives which helps them to rising the importance of synthetic biology. This combined public-private sector capital is creating a robust ecosystem that drives new technologies, applications, and products in healthcare, agriculture, and the environmental sectors.

Market Restraints:

Regulatory challenges in synthetic genomics impose hurdles that hinder market growth in upcoming years.

In humans and agricultural organisms, operating genomes increases major ethical concerns which can’t be ignored. These things restrict the potential outcomes of altering genetic material on ecosystems, biodiversity, and human health. Major companies operating the synthetic genomics market must steer the various difficult regulatory challenges such as lengthy approval processes, increased scrutiny, and some of the investment obstacles which are hamper the market growth.

Despite these challenges, investments in synthetic genomics continue to flow. For instance, the Carl-Zeiss-Stiftung (CZS), is financing the establishment of the Center for Synthetic Genomics over a period of six years, allocating a total of US$ 12.9 million to support research and address ethical concerns. This initiative highlights the balance that must be struck between fostering innovation and ensuring responsible practices in synthetic genomics.

Opportunity Factors:

Transforming Healthcare Through Customized Treatments is the Great Opportunity for Startups in Synthetic Genomic Market.

Consumers change their preference to personalized medicine due to transforming the healthcare landscape, creating significant opportunities in synthetic genomics. Personalized medicine highlights customizing medical treatments such as individual unique genetic makeup, lifestyle, and environmental factors. These factors particularly projecting in oncology and controlling rare genetic disorders, where traditional one-size-fits-all treatments may be ineffective or carry severe side effects. By influencing advancement in synthetic genomics, researchers and scientists are focusing on developing personalized therapies which can specifically target the genetic mutations or alterations present in patients’ tumor or conditions.

For example, Synthetic genomics enables the creation of custom gene therapies to fix defective genes or add new ones to fight diseases. This targeted method makes treatments more effective and reduces side effects, improving patient health and streamlining healthcare. As personalized medicine grows in demand, synthetic genomics will be key in shaping future treatments and addressing important gaps in patient care.

Geography Analysis:

Technological advancement in Biotechnology Drives the Market Growth in the North America Region.

The North America region holds the first position in the synthetics genomics market, especially in the biotechnology industry due to research and development infrastructure. The United States government is providing too much support for genomic research, which can help it to be characterized by the various leading biotech firms, academic institutions, and research organizations focusing on synthetic genomics and biology.

Furthermore, this collaborative ecosystem has resulted in increased investments in genomics research, particularly in response to the rising prevalence of genetic disorders; for instance, the National Center for Biotechnology Information reported in November 2021 that genetic illnesses were found in 9.4% of pediatric patients, with 44.7% of these cases occurring in critically ill newborns. Furthermore, 13.17 million patients in the U.S. are affected by unique genetic disorders, underscoring the growing demand for personalized medicine and driving the synthetic geonomics market.

Moreover, prominent players such as Illumina, Thermo Fisher Scientific, and Agilent Technologies reinforce North America's leadership in the synthetic genomics arena. However, the grouping of strong market presence, innovative research and positive regulatory changes fosters an atmosphere of innovation and commercial application, which are the major driving factors in the North America region.

Key Benefits of Global Synthetic Genomics Market Report:

• Global Synthetic Genomics market report covers in-depth historical and forecast analysis.
• Global Synthetic Genomics market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, and Regional and Country Level.
• Global Synthetic Genomics market report helps to identify opportunities in the marketplace.
• Global Synthetic Genomics market report covers extensive analysis of emerging trends and competitive landscape.

Global Synthetic Genomics Market Segmentation:

By Product:

• Synthetic DNA
• Synthetic Cells
• Enzymes
• Oligonucleotides
• Others

By Technology:

• Gene Synthesis
• DNA Sequencing
• Gene Editing
  • CRISPR
  • TALENs
  • Zinc Finger Nucleases
• Cloning and Subcloning
• Bioinformatics Tools
• Pathway Engineering
• Others

By Application:  

• Healthcare and Pharmaceuticals
  • Drug Development
  • Gene Therapy
  • Vaccine Development
• Agriculture
  • Genetically Modified Crops
  • Livestock Engineering
• Industrial Biotechnology
  • Biofuels
  • Bioplastics
  • Biochemical Production
• Environmental Applications
  • Waste Treatment
  • Bioremediation
• Synthetic Biology Research

By End-User:  

• Academic and Research Institutions
• Biotechnology and Pharmaceutical Companies
• Agriculture Companies
• Contract Research Organizations (CROs)
• Environmental Agencies

By Regional & Country Level:

• North America
  • S.
  • Canada
• Europe
  • K.
  • France
  • Germany
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Southeast Asia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa